FDA Grants Priority Review to Genentechs Tecentriq Monotherapy as Firstline Treatment of Certain People With Advanced Nonsmall Cell Lung Cancer

ÂGenentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that the U.S. Food and Drug Administration FDA has accepted the companys supplemental Biologics License Application sBLA and granted Priority Review for Tecentriq atezolizumab ...